# Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

> **NCT01217450** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 33 (actual)

## Conditions studied

- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** selumetinib
- **BIOLOGICAL:** cetuximab
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01217450
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2012-12
- **Final completion:** 2014-05
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217450, "Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01217450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*